Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects

• Published in: Oncotarget Vol. 8; no. 10; pp. 16122 - 16143
• Main Authors: Nagaraj, Siranjeevi, Laskowska-Kaszub, Katarzyna, Dębski, Konrad J., Wojsiat, Joanna, Dąbrowski, Michał, Gabryelewicz, Tomasz, Kuźnicki, Jacek, Wojda, Urszula
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 07.03.2017
• Subjects: Aged; Alzheimer Disease - blood; Alzheimer Disease - diagnosis; Alzheimer Disease - genetics; Amyloid beta-Peptides - cerebrospinal fluid; Biomarkers - blood; Biomarkers - cerebrospinal fluid; Dementia - blood; Dementia - diagnosis; Dementia - genetics; Diagnosis, Differential; Early Diagnosis; Female; Gene Expression Profiling - methods; Humans; Male; MicroRNAs - blood; MicroRNAs - genetics; Middle Aged; Peptide Fragments - cerebrospinal fluid; Research Paper: Gerotarget (Focus on Aging); Reverse Transcriptase Polymerase Chain Reaction; tau Proteins - cerebrospinal fluid; microRNA; Gerotarget; mild cognitive impairment; early Alzheimer’s disease; biomarker; Alzheimer`s disease
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.15109

Alzheimer's disease (AD) is the most common age-related dementia. Among its major challenges is identifying molecular signatures characteristic for the early AD stage in patients with Mild Cognitive Impairment (MCI-AD), which could serve for deciphering the AD pathomechanism and also as non-invasive, easy-to-access biomarkers. Using qRT-PCR we compared the microRNA (miRNA) profiles in blood plasma of 15 MCI-AD patients, whose diagnoses were confirmed by cerebrospinal fluid (CSF) biomarkers, with 20 AD patients and 15 non-demented, age-matched individuals (CTR).To minimize methodological variability, we adhered to standardization of blood and CSF assays recommended by the international Joint Programming for Neurodegenerative Diseases (JPND) BIOMARKAPD consortium, and we employed commercially available Exiqon qRT-PCR-assays. In the first screening, we assessed 179 miRNAs of plasma. We confirmed 23 miRNAs reported earlier as AD biomarker candidates in blood and found 26 novel differential miRNAs between AD and control subjects. For representative 15 differential miRNAs, the TargetScan, MirTarBase and KEGG database analysis indicated putative protein targets among such AD hallmarks as MAPT (Tau), proteins involved in amyloidogenic proteolysis, and in apoptosis. These 15 miRNAs were verified in separate, subsequent subject groups. Finally, 6 miRNAs (3 not yet reported in AD context and 3 reported in AD blood) were selected as the most promising biomarker candidates differentiating early AD from controls with the highest fold changes (from 1.32 to 14.72), consistent significance, specificities from 0.78 to 1 and sensitivities from 0.75 to 1. (patent pending, PCT/IB2016/052440).